Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
A Bruton's tyrosine kinase (BTK) inhibitor that indirectly affects BLNK-mediated signaling by disrupting the B cell receptor pathway. It was investigated for B cell malignancies and autoimmune disorders. | ||||||
R788 | 901119-35-5 | sc-364597 sc-364597A | 2 mg 50 mg | $405.00 $4000.00 | 2 | |
A spleen tyrosine kinase (SYK) inhibitor that impacts downstream signaling events involving BLNK. It was studied for immune thrombocytopenic purpura (ITP) and other autoimmune conditions. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Another BTK inhibitor that interferes with BLNK-associated signaling pathways. It has been explored in various B cell-related disorders, including certain lymphomas. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
A phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor that could indirectly affect BLNK-mediated PI3K signaling. It was researched for B cell malignancies like chronic lymphocytic leukemia (CLL). | ||||||
Spebrutinib | 1202757-89-8 | sc-507524 | 100 mg | $375.00 | ||
A BTK inhibitor that might influence BLNK signaling pathways, and was being investigated for B cell disorders and autoimmune diseases. | ||||||
GS 9973 | 1229208-44-9 | sc-490337 sc-490337A sc-490337B sc-490337C sc-490337D | 10 mg 50 mg 100 mg 500 mg 1 g | $250.00 $878.00 $1353.00 $5500.00 $9000.00 | ||
A SYK inhibitor with potential effects on BLNK-related signaling events, studied in various hematologic malignancies. | ||||||
IPI 145 | 1201438-56-3 | sc-488318 | 5 mg | $317.00 | ||
A dual PI3Kδ/PI3Kγ inhibitor that could impact BLNK-associated PI3K signaling. It was explored for lymphoid malignancies. | ||||||
Zanubrutinib | 1691249-45-2 | sc-507434 | 5 mg | $360.00 | ||
Yet another BTK inhibitor that modulates BLNK-mediated pathways. It was researched for B cell lymphomas and other conditions. | ||||||
Tirabrutinib | 1351636-18-4 | sc-507435 | 10 mg | $138.00 | ||
A reversible BTK inhibitor that might affect BLNK-associated signaling cascades, undergoing investigation for B cell malignancies. | ||||||
TGR-1202 | 1532533-67-7 | sc-507436 | 25 mg | $286.00 | ||
A dual PI3Kδ/CK1ε inhibitor that could influence BLNK-related PI3K signaling pathways. It was being studied for hematologic cancers. | ||||||